Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 16 | 2021 | 282 | 6.030 |
Why?
|
| Kidney Failure, Chronic | 17 | 2021 | 543 | 5.160 |
Why?
|
| Catheterization, Central Venous | 4 | 2017 | 62 | 1.910 |
Why?
|
| African Americans | 13 | 2019 | 1425 | 1.800 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2017 | 48 | 1.630 |
Why?
|
| Kidney Diseases | 9 | 2021 | 249 | 1.520 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2018 | 1428 | 1.460 |
Why?
|
| Apolipoproteins | 10 | 2019 | 200 | 1.300 |
Why?
|
| Albuminuria | 5 | 2015 | 181 | 1.240 |
Why?
|
| Lipoproteins, HDL | 9 | 2016 | 251 | 1.130 |
Why?
|
| Uric Acid | 2 | 2018 | 27 | 1.040 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 291 | 0.940 |
Why?
|
| Catheters, Indwelling | 2 | 2014 | 43 | 0.840 |
Why?
|
| Humans | 40 | 2021 | 32005 | 0.760 |
Why?
|
| Fluid Therapy | 1 | 2019 | 24 | 0.680 |
Why?
|
| Middle Aged | 24 | 2019 | 11817 | 0.660 |
Why?
|
| Male | 27 | 2019 | 19165 | 0.640 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2015 | 835 | 0.640 |
Why?
|
| Catheter-Related Infections | 2 | 2019 | 10 | 0.640 |
Why?
|
| Psoas Muscles | 1 | 2018 | 19 | 0.610 |
Why?
|
| Patient Selection | 1 | 2019 | 276 | 0.590 |
Why?
|
| Hyperuricemia | 2 | 2018 | 11 | 0.590 |
Why?
|
| Female | 25 | 2019 | 19959 | 0.580 |
Why?
|
| Heparin | 1 | 2017 | 73 | 0.560 |
Why?
|
| Anticoagulants | 1 | 2017 | 122 | 0.530 |
Why?
|
| Molecular Motor Proteins | 3 | 2012 | 58 | 0.530 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 69 | 0.530 |
Why?
|
| Myosin Heavy Chains | 3 | 2012 | 89 | 0.530 |
Why?
|
| Aged | 15 | 2019 | 10301 | 0.520 |
Why?
|
| Kidney | 4 | 2021 | 518 | 0.520 |
Why?
|
| Kidney Glomerulus | 2 | 2014 | 30 | 0.510 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2013 | 1062 | 0.480 |
Why?
|
| Hypertension | 2 | 2012 | 959 | 0.460 |
Why?
|
| Diabetes Complications | 1 | 2015 | 177 | 0.450 |
Why?
|
| Receptors, Notch | 2 | 2010 | 16 | 0.440 |
Why?
|
| Risk Factors | 11 | 2017 | 3876 | 0.430 |
Why?
|
| Gout | 1 | 2012 | 14 | 0.420 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 224 | 0.420 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 48 | 0.420 |
Why?
|
| Serum Albumin | 1 | 2012 | 54 | 0.420 |
Why?
|
| Proteinuria | 1 | 2012 | 59 | 0.400 |
Why?
|
| Minocycline | 1 | 2011 | 11 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 324 | 0.390 |
Why?
|
| Cognition Disorders | 1 | 2015 | 385 | 0.390 |
Why?
|
| Environmental Exposure | 1 | 2012 | 91 | 0.390 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 143 | 0.390 |
Why?
|
| Length of Stay | 1 | 2012 | 314 | 0.380 |
Why?
|
| Bacteremia | 1 | 2011 | 65 | 0.370 |
Why?
|
| Fatty Acids | 1 | 2010 | 98 | 0.350 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3990 | 0.340 |
Why?
|
| Prognosis | 5 | 2018 | 1497 | 0.340 |
Why?
|
| Hospitalization | 1 | 2012 | 470 | 0.340 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 184 | 0.330 |
Why?
|
| DNA | 1 | 2010 | 226 | 0.320 |
Why?
|
| Risk Assessment | 4 | 2019 | 1426 | 0.310 |
Why?
|
| Glomerular Filtration Rate | 6 | 2015 | 308 | 0.310 |
Why?
|
| Brain | 1 | 2015 | 951 | 0.300 |
Why?
|
| Acetyl-CoA Carboxylase | 3 | 2013 | 23 | 0.300 |
Why?
|
| Treatment Outcome | 3 | 2021 | 3306 | 0.270 |
Why?
|
| Signal Transduction | 1 | 2010 | 682 | 0.270 |
Why?
|
| Adult | 14 | 2019 | 9345 | 0.270 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 21 | 0.270 |
Why?
|
| Polyomavirus Infections | 2 | 2018 | 21 | 0.270 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1128 | 0.260 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 517 | 0.250 |
Why?
|
| North Carolina | 3 | 2021 | 1514 | 0.240 |
Why?
|
| Genetic Variation | 3 | 2015 | 244 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 73 | 0.210 |
Why?
|
| Prevalence | 3 | 2016 | 981 | 0.210 |
Why?
|
| Adolescent | 4 | 2021 | 3539 | 0.200 |
Why?
|
| Incidence | 2 | 2016 | 1199 | 0.200 |
Why?
|
| Age Factors | 2 | 2016 | 1188 | 0.200 |
Why?
|
| Time Factors | 3 | 2017 | 2149 | 0.200 |
Why?
|
| Ultrafiltration | 2 | 2019 | 11 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2013 | 256 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2017 | 2282 | 0.180 |
Why?
|
| Quality of Life | 2 | 2016 | 946 | 0.180 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3509 | 0.170 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 245 | 0.170 |
Why?
|
| United States | 3 | 2015 | 3939 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2012 | 1817 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 547 | 0.170 |
Why?
|
| Survival Rate | 2 | 2018 | 877 | 0.160 |
Why?
|
| Knowledge | 1 | 2018 | 14 | 0.160 |
Why?
|
| Weight Gain | 1 | 2019 | 117 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 143 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2265 | 0.160 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 26 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2021 | 348 | 0.150 |
Why?
|
| Outpatients | 1 | 2018 | 57 | 0.150 |
Why?
|
| Cisplatin | 1 | 2018 | 76 | 0.150 |
Why?
|
| Health Status Indicators | 1 | 2018 | 73 | 0.150 |
Why?
|
| JC Virus | 2 | 2018 | 20 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 767 | 0.150 |
Why?
|
| African Continental Ancestry Group | 3 | 2016 | 363 | 0.150 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 107 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 483 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 154 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 130 | 0.140 |
Why?
|
| Body Composition | 1 | 2018 | 397 | 0.130 |
Why?
|
| Linear Models | 2 | 2014 | 447 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2014 | 508 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 684 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 60 | 0.120 |
Why?
|
| Young Adult | 4 | 2018 | 2636 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2015 | 76 | 0.120 |
Why?
|
| Mesangial Cells | 1 | 2014 | 10 | 0.120 |
Why?
|
| Comorbidity | 1 | 2016 | 566 | 0.120 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 40 | 0.120 |
Why?
|
| Genotype | 4 | 2019 | 733 | 0.110 |
Why?
|
| Autoantigens | 1 | 2013 | 16 | 0.110 |
Why?
|
| Glomerulonephritis | 1 | 2013 | 21 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 155 | 0.110 |
Why?
|
| Podocytes | 2 | 2014 | 20 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 371 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1531 | 0.110 |
Why?
|
| Disease Progression | 2 | 2019 | 594 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 918 | 0.110 |
Why?
|
| European Continental Ancestry Group | 2 | 2015 | 1166 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 80 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 148 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 753 | 0.100 |
Why?
|
| Family Health | 1 | 2012 | 76 | 0.100 |
Why?
|
| Metabolism | 1 | 2011 | 7 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 162 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 135 | 0.100 |
Why?
|
| Genome, Human | 1 | 2011 | 132 | 0.090 |
Why?
|
| Thienamycins | 1 | 2010 | 4 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2011 | 238 | 0.090 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 30 | 0.090 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2010 | 38 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 876 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 268 | 0.090 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 146 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 923 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2010 | 110 | 0.080 |
Why?
|
| Critical Illness | 1 | 2010 | 87 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1328 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 538 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2013 | 220 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1175 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 898 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2016 | 833 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 297 | 0.050 |
Why?
|
| Phenotype | 2 | 2013 | 632 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 2013 | 349 | 0.040 |
Why?
|
| Mice | 2 | 2015 | 2484 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 301 | 0.040 |
Why?
|
| Animals | 3 | 2015 | 7541 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 19 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 94 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 52 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 285 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 359 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 88 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 495 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 261 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 44 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 141 | 0.030 |
Why?
|
| Cystatin C | 1 | 2013 | 31 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 51 | 0.030 |
Why?
|
| Cell Line | 1 | 2014 | 435 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 259 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2013 | 54 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 726 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 109 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 608 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 109 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 321 | 0.030 |
Why?
|
| Heredity | 1 | 2012 | 13 | 0.030 |
Why?
|
| Pedigree | 1 | 2012 | 140 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 230 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2013 | 443 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 198 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1595 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 338 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 86 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 220 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 484 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 881 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2011 | 462 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 633 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 519 | 0.020 |
Why?
|